Puma Biotechnology (PBYI) Retained Earnings (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly Retained Earnings came in at -$31000.0 in Q1 2026, up 100.0% YoY from -$15500.2 in Q1 2025, and down 186.11% on a QoQ basis from $36000.0 in Q4 2025.
Puma Biotechnology (PBYI) Retained Earnings (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of Retained Earnings data on file, last reported at -$31000.0 in Q1 2026.
- Quarterly Retained Earnings rose 100.0% year-over-year to -$31000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31000.0 (up 100.0% YoY) and the FY2025 annual result came in at $36000.0, up 100.0% from the prior year.
- Retained Earnings declined to -$31000.0 in Q1 2026, from $36000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $36000.0 in Q4 2025 to a low of -$1.4 billion in Q1 2022.
- A 5-year average of -$894.7 million and a median of -$1.3 billion in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 136078800.0% — and 2025, when it jumped 100.0%.
- Tracing PBYI's Retained Earnings over 5 years: stood at -$1.4 billion in 2022, then gained by 1.15% to -$1.3 billion in 2023, then gained by 2.25% to -$1.3 billion in 2024, then jumped by 100.0% to $36000.0 in 2025, then sank by 186.11% to -$31000.0 in 2026.
- The last three Retained Earnings figures came in at -$31000.0 (Q1 2026), $36000.0 (Q4 2025), and $19000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | -1.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 Bn |
| Mar 31, 2026 | -31,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | -1.31 Bn |
| Mar 31, 2025 | -1.31 Bn |
| Dec 31, 2024 | -1.31 Bn |
| Sep 30, 2024 | -1.33 Bn |
| Jun 30, 2024 | -1.35 Bn |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | -1.35 Bn |
| Sep 30, 2023 | -1.36 Bn |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -1.37 Bn |
| Jun 30, 2022 | -1.36 Bn |
| Mar 31, 2022 | -1.37 Bn |
| Dec 31, 2021 | -1.37 Bn |
| Sep 30, 2021 | -1.37 Bn |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | -1.32 Bn |